Literature DB >> 12210964

Microsurgical reconstruction of lower limb bone defects following tumor resection using vascularized fibula osteoseptocutaneous flap.

Tarek Abdalla El-Gammal1, Amr El-Sayed, Mohammed M Kotb.   

Abstract

This study included 25 patients with lower limb tumors who had wide local resection and reconstruction by vascularized fibula osteoseptocutaneous flap, and who had their surgery performed at least 24 months before the end of the study. The average age at operation was 23.5 years. Twenty-three tumors were malignant;16 were staged as high-grade sarcomas (stage IIA, stage IIB, and Ewing's sarcoma). Tumor volume averaged 293.2 cc (range, 41.4-860). The resulting defect after tumor resection averaged 16 cm (range, 9-20 cm). The fibula was inserted as a single strut in 21 patients, and as a double-barrel construct in 4 patients. Fixation was augmented by interlocking nail in 11 cases, bridge plate in 9 cases, and external fixator in 5 cases. Twenty-four (96%) flaps survived. All grafts united in an average period of 4.5 months (range, 3-8 months) after transfer. Two secondary procedures were necessary to achieve graft union. Full weight bearing was possible after an average period of 7.5 months (range, 5-14 months). Significant hypertrophy (> or =30% of original fibular diameter) occurred in 85% of patients after an average period of 10 months from the index operation. In the latest follow-up radiographs (mean, 32 months), the degree of hypertrophy averaged 90% (range, 30-200%). Graft fracture occurred in three patients, and all healed conservatively. The Musculoskeletal Tumor Society rating score (MTSRS) averaged 21.2 points at the end of the first postoperative year, and 23.6 at the end of the study. Copyright 2002 Wiley Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12210964     DOI: 10.1002/micr.22501

Source DB:  PubMed          Journal:  Microsurgery        ISSN: 0738-1085            Impact factor:   2.425


  7 in total

1.  Comparison of 39 post-traumatic tibia bone transports performed with and without the use of an intramedullary rod: the long-term outcomes.

Authors:  Emmanouil Liodakis; Mohamed Kenawey; Christian Krettek; Ulrich Wiebking; Stefan Hankemeier
Journal:  Int Orthop       Date:  2010-07-22       Impact factor: 3.075

2.  [Bilateral fibula graft. Biological reconstruction following resection of malignant bone tumors].

Authors:  P-U Tunn; T K Moesta; H Delbrück
Journal:  Chirurg       Date:  2006-10       Impact factor: 0.955

Review 3.  Vascularized fibular grafts for the treatment of long bone defects: pros and cons. A systematic review and meta-analysis.

Authors:  Christian Candrian; Giuseppe Filardo; Pietro Feltri; Luca Solaro; Costantino Errani; Guglielmo Schiavon
Journal:  Arch Orthop Trauma Surg       Date:  2021-06-10       Impact factor: 3.067

4.  Biomechanical analysis of the impact of fibular osteotomies at tibiotalar joint: A cadaveric study.

Authors:  Lin Yang; Hong-Zhang Xu; Dong-Zhu Liang; Wei Lu; Shi-Zheng Zhong; Jun Ouyang
Journal:  Indian J Orthop       Date:  2012-09       Impact factor: 1.251

Review 5.  A Novel Treatment of a 65-Year-Old Woman with a Neglected Type IIIB Open Fracture of the Tibia with Inadequate Soft Tissue Coverage and Periosteal Stripping Requiring an Ilizarov Approach to Bone and Soft Tissue Lengthening and Reconstruction: A Case Report and Review of the Literature.

Authors:  Antonios Kouzelis; Ioannis N Vrachnis; Alexandros Vris; Petros Zampakis; Zinon T Kokkalis; Andreas Panagopoulos
Journal:  Am J Case Rep       Date:  2020-12-06

6.  Intercalary reconstructions with vascularised fibula and allograft after tumour resection in the lower limb.

Authors:  Katharina Rabitsch; Werner Maurer-Ertl; Ulrike Pirker-Frühauf; Christine Wibmer; Andreas Leithner
Journal:  Sarcoma       Date:  2013-05-23

7.  Bilateral fibular graft: biological reconstruction after resection of primary malignant bone tumors of the lower limb.

Authors:  Maya Niethard; Carmen Tiedke; Dimosthenis Andreou; Frank Traub; Mario Kuhnert; Mathias Werner; Per-Ulf Tunn
Journal:  Sarcoma       Date:  2013-04-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.